摘要
目的观察左卡尼汀联合重组人促红细胞生成素治疗肾性贫血的临床效果。方法将48例尿毒症且具有肾性贫血的维持性血液透析患者随机分为对照组和治疗组,每组24例。两组患者均静脉注射重组人促红细胞生成素,2次/周,3000 U/次。治疗组于血液透析后静脉注射左卡尼汀1.0 g,2次/周。3个月为1个观察周期。结果治疗3个月后,治疗组血红蛋白、血细胞比容升高水平显著高于对照组,差异有统计学意义(P<0.05)。结论左卡尼汀联合重组人促红细胞生成素可增强肾性贫血血液透析患者的临床效果。
Objecttive To observe the clinical effect of L-carnitine combined with recombinant human erythropoietin in treatment of renal anemia.Methods 48 cases of patients with uremia and with renal anemia in maintenance hemodialy- sis were randomly divided into control group （24 cases） and treatment group （24cases）,recombinant human erythropoi- etin intravenous injection was given to the two groups,2 times a week,3000 U one time.l.0 g L-carnitine intravenous injection was given to the treatment group after hemodialysis,2 times a week.The observation period was 3 months.Re- sults After 3 months treatment,the increasing of hemoglobin and hematocrit in the treatment group was significantly higher than that in the control group respectively,the difference was significant （P〈0.05）.Conclusion L-carnitine com- bined with recombinant human erythropoietin can improve the treatment efficacy of hemodialysis patients with renal anemia.
出处
《中国当代医药》
2014年第14期109-110,共2页
China Modern Medicine
